MedTrace Logo

A Trial of NT-I7 in COVID-19 (SPESELPIS)

NCT04501796 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-07-14

No results posted yet for this study

Summary

The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19):

* Safety of a single dose of NT-I7
* The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.

Conditions

Interventions

DRUG

Double-Blind NT-I7

Administered by intramuscular (IM) injection

DRUG

Double-Blind Placebo

Placebo

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • University of Nebraska

    collaborator OTHER

  • NeoImmuneTech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-27
Primary Completion
2021-07-21
Completion
2023-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04501796 on ClinicalTrials.gov